Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.58 |
| ▸ | PPARG | P37231 | 8/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689756 | 1.00 | PPARA (0.58) | PPARAPPARGFFAR1PPARDCA12 | |
| SCHEMBL5690235 | 1.00 | PPARA (0.58) | PPARAPPARGFFAR1PPARDCA12 | |
| SCHEMBL6092773 | 0.90 | PPARA (0.51) | PPARAPPARGFFAR1PPARD | |
| SCHEMBL6092981 | 0.90 | PPARA (0.51) | PPARAPPARGFFAR1PPARD | |
| SCHEMBL6092983 | 0.83 | PPARA (0.50) | PPARAPPARGFFAR1PPARDCA12 | |
| SCHEMBL6092777 | 0.83 | PPARA (0.50) | PPARAPPARGFFAR1PPARDCA12 | |
| SCHEMBL3100628 | 0.82 | PPARA (0.71) | PPARAPPARGFFAR1PPARD | |
| SCHEMBL3946198 | 0.82 | PPARA (0.71) | PPARAPPARGFFAR1PPARD | |
| SCHEMBL3100619 | 0.82 | PPARA (0.71) | PPARAPPARGFFAR1PPARD | |
| SCHEMBL5474463 | 0.81 | PPARA (0.70) | PPARAPPARGFFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199857-A1 | Therapeutic agents | ASTRAZENECA UK LIMITED (GB) | 2006-09-07 | — | — | US | claimed |
| US-20060199857-A1 | Therapeutic agents | ASTRAZENECA UK LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| EP-1638927-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113282-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199857-A1 | Therapeutic agents | PNLIP, LIPC, GPR119 | PPARA 27/4885PPARG 38/4885FFAR1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.